Alexion Pharmaceuticals

• Archives
• Highlights
• Media Kit
• Inquiries

Highlights

• Soliris Approved in United States and European Union for Treatment of Adult and Pediatric Patients with aHUS

  Soliris® (eculizumab) is now approved by the U.S. Food and Drug Administration (FDA) and by the European Commission (EC) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS). The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of Soliris in patients with aHUS. Soliris is not indicated for the treatment of patients with Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS). Click here to read the FDA approval press release, and click here to read the EC approval press release. Click here for U.S. Prescribing Information. Click here for Important Safety information.

• Alexion OneSource Program to Serve U.S. Patients with aHUS

  Alexion is expanding its OneSource™ Treatment Support Program to U.S. patients with atypical hemolytic uremic syndrome (aHUS) now that the FDA has approved Soliris for this use. Since 2007, OneSource has provided personalized, ongoing support for patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, life-threatening blood disorder. Patients and families in the United States affected by aHUS can call 1-888-SOLIRIS to speak with an Alexion Nurse Case Manager, who can help answer questions about the OneSource program, discuss funding options for Soliris, provide education on disease and drug, and provide ongoing treatment support.

• Hear from Members of the aHUS Community

  Members of the aHUS community discuss their experience living with aHUS and the significance of the FDA approval of Soliris as a treatment for this devastating disease. Play Video.

• Soliris®

  Soliris® (eculizumab) is the first therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Visit the new Soliris site, www.soliris.net , to learn more about Soliris and PNH, read patient stories, join our patient support program and get updates on the latest research.

• A Rare Opportunity To Make A Difference

  Alexion is now hiring for a range of positions, from marketing to research and development and support functions. We’re looking for people who share our passion and commitment to transforming the lives of patients with life-threatening ultra-rare diseases. We invite you to learn more about our company and our culture by meeting our team and reviewing our career opportunities.